Adage Capital Partners
IMNM icon

Adage Capital Partners’s Immunome IMNM Stock Holding History

Adage Capital Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-775,000
Closed -$5.22M – 895
2025
Q1 		$5.22M Buy
775,000
+275,000
+55% +$2.64M 0.01% 693
2024
Q4 		$5.31M Buy
500,000
+280,000
+127% +$3.38M 0.01% 711
2024
Q3 		$3.22M Hold
220,000
– – 0.01% 749
2024
Q2 		$2.66M Buy
+220,000
New +$3.44M ﹤0.01% 765

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Adage Capital Partners's IMNM Position: Q2 2025 in Review

Adage Capital Partners sold out of Immunome (IMNM) in Q2 2025, closing a stake of 775,000 shares — an estimated $5.22M sold.

Adage Capital Partners first reported a position in IMNM in Q2 2024 and held it in 4 quarters. The position peaked at $5.31M in Q4 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

  • Adage Capital Partners reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
  • Adage Capital Partners sold 775,000 Immunome shares in Q2 2025, an estimated $5.22M.
  • Adage Capital Partners first reported a position in Immunome in Q2 2024 and held it in 4 quarters.
  • Adage Capital Partners's Immunome position peaked at $5.31M in Q4 2024.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Adage Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.